Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roderick L Beijersbergen

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Molecular Cancer Therapeutics|February 15, 2018
PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in NeuroblastomaDiede Brunen, Romy C de Vries, Cor Lieftink, et al.
Bio-Protocol|December 12, 2022
An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell AdhesionYvonne J Thus, Martin F M De Rooij, Roderick L Beijersbergen, et al.
Plos One|March 12, 2009
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathwayJasper Mullenders, Armida W M Fabius, Mandy Madiredjo, et al.
Nature Biotechnology|April 26, 2016
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genesBastiaan Evers, Katarzyna Jastrzebski, Jeroen P M Heijmans, et al.
NAR Cancer|November 5, 2025
Exploiting nanopore sequencing advances for tRNA sequencing of human cancer modelsAdva Kochavi, Arno Velds, Maya Suzuki, et al.
Nature Protocols|October 8, 2025
Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular statesGabriele Casagrande Raffi, Hendrik J Kuiken, Cor Lieftink, et al.
Nucleic Acids Research|March 25, 2015
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interferenceRodolphe Barrangou, Amanda Birmingham, Stefan Wiemann, et al.
Journal of Cellular and Molecular Medicine|January 4, 2012
Identification of F-box only protein 7 as a negative regulator of NF-kappaB signallingHendrik J Kuiken, David A Egan, Heike Laman, et al.
Oncotarget|July 5, 2016
Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancerSedef Iskit, Cor Lieftink, Pasi Halonen, et al.
Nature Communications|April 20, 2022
A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathwaysMartin F M de Rooij, Yvonne J Thus, Nathalie Swier, et al.
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Molecular Cancer Therapeutics|February 15, 2018
PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in NeuroblastomaDiede Brunen, Romy C de Vries, Cor Lieftink, et al.
Bio-Protocol|December 12, 2022
An Unbiased CRISPR-Cas9 Screening Method for the Identification of Positive and Negative Regulatory Proteins of Cell AdhesionYvonne J Thus, Martin F M De Rooij, Roderick L Beijersbergen, et al.
Plos One|March 12, 2009
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathwayJasper Mullenders, Armida W M Fabius, Mandy Madiredjo, et al.
Nature Biotechnology|April 26, 2016
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genesBastiaan Evers, Katarzyna Jastrzebski, Jeroen P M Heijmans, et al.
NAR Cancer|November 5, 2025
Exploiting nanopore sequencing advances for tRNA sequencing of human cancer modelsAdva Kochavi, Arno Velds, Maya Suzuki, et al.
Nature Protocols|October 8, 2025
Inducible CRISPR-Cas9 screening platform to interrogate non-proliferative cellular statesGabriele Casagrande Raffi, Hendrik J Kuiken, Cor Lieftink, et al.
Nucleic Acids Research|March 25, 2015
Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interferenceRodolphe Barrangou, Amanda Birmingham, Stefan Wiemann, et al.
Journal of Cellular and Molecular Medicine|January 4, 2012
Identification of F-box only protein 7 as a negative regulator of NF-kappaB signallingHendrik J Kuiken, David A Egan, Heike Laman, et al.
Oncotarget|July 5, 2016
Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancerSedef Iskit, Cor Lieftink, Pasi Halonen, et al.
Nature Communications|April 20, 2022
A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathwaysMartin F M de Rooij, Yvonne J Thus, Nathalie Swier, et al.
Pageof 10